Logo image of ERF.PA

EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis

EPA:ERF - Euronext Paris - Matif - FR0014000MR3 - Common Stock - Currency: EUR

67.52  +0.72 (+1.08%)

Fundamental Rating

5

Overall ERF gets a fundamental rating of 5 out of 10. We evaluated ERF against 20 industry peers in the Life Sciences Tools & Services industry. ERF has an excellent profitability rating, but there are some minor concerns on its financial health. ERF has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year ERF was profitable.
ERF had a positive operating cash flow in the past year.
Each year in the past 5 years ERF has been profitable.
In the past 5 years ERF always reported a positive cash flow from operatings.
ERF.PA Yearly Net Income VS EBIT VS OCF VS FCFERF.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

ERF has a better Return On Assets (3.24%) than 65.00% of its industry peers.
ERF has a Return On Equity of 6.61%. This is in the better half of the industry: ERF outperforms 70.00% of its industry peers.
ERF's Return On Invested Capital of 9.18% is amongst the best of the industry. ERF outperforms 85.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ERF is in line with the industry average of 6.97%.
The 3 year average ROIC (8.70%) for ERF is below the current ROIC(9.18%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.24%
ROE 6.61%
ROIC 9.18%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ERF.PA Yearly ROA, ROE, ROICERF.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

Looking at the Profit Margin, with a value of 5.08%, ERF is in line with its industry, outperforming 55.00% of the companies in the same industry.
In the last couple of years the Profit Margin of ERF has grown nicely.
ERF has a better Operating Margin (14.97%) than 65.00% of its industry peers.
In the last couple of years the Operating Margin of ERF has grown nicely.
With a Gross Margin value of 22.33%, ERF is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
ERF's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 14.97%
PM (TTM) 5.08%
GM 22.33%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
ERF.PA Yearly Profit, Operating, Gross MarginsERF.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

More info and screens

4

2. Health

2.1 Basic Checks

ERF has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ERF has less shares outstanding
Compared to 5 years ago, ERF has more shares outstanding
ERF has a better debt/assets ratio than last year.
ERF.PA Yearly Shares OutstandingERF.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ERF.PA Yearly Total Debt VS Total AssetsERF.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

ERF has an Altman-Z score of 2.86. This is not the best score and indicates that ERF is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.86, ERF perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
The Debt to FCF ratio of ERF is 4.57, which is a neutral value as it means it would take ERF, 4.57 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ERF (4.57) is better than 75.00% of its industry peers.
ERF has a Debt/Equity ratio of 0.59. This is a neutral value indicating ERF is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.59, ERF perfoms like the industry average, outperforming 55.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 4.57
Altman-Z 2.86
ROIC/WACC1.27
WACC7.25%
ERF.PA Yearly LT Debt VS Equity VS FCFERF.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

A Current Ratio of 1.16 indicates that ERF should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.16, ERF is doing worse than 80.00% of the companies in the same industry.
ERF has a Quick Ratio of 1.09. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.09, ERF is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.09
ERF.PA Yearly Current Assets VS Current LiabilitesERF.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.98% over the past year.
The Earnings Per Share has been growing by 18.34% on average over the past years. This is quite good.
The Revenue has been growing slightly by 6.70% in the past year.
Measured over the past years, ERF shows a quite strong growth in Revenue. The Revenue has been growing by 8.78% on average per year.
EPS 1Y (TTM)14.98%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%13.46%
Revenue 1Y (TTM)6.7%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%6.87%

3.2 Future

ERF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.47% yearly.
Based on estimates for the next years, ERF will show a small growth in Revenue. The Revenue will grow by 6.47% on average per year.
EPS Next Y15.29%
EPS Next 2Y14.58%
EPS Next 3Y14%
EPS Next 5Y13.47%
Revenue Next Year5.99%
Revenue Next 2Y6.12%
Revenue Next 3Y6.4%
Revenue Next 5Y6.47%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ERF.PA Yearly Revenue VS EstimatesERF.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B
ERF.PA Yearly EPS VS EstimatesERF.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4 5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 20.46, which indicates a rather expensive current valuation of ERF.
Based on the Price/Earnings ratio, ERF is valued cheaper than 90.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.93, ERF is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 18.96, the valuation of ERF can be described as rather expensive.
80.00% of the companies in the same industry are more expensive than ERF, based on the Price/Forward Earnings ratio.
ERF's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 35.31.
Industry RankSector Rank
PE 20.46
Fwd PE 18.96
ERF.PA Price Earnings VS Forward Price EarningsERF.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

ERF's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ERF is cheaper than 90.00% of the companies in the same industry.
100.00% of the companies in the same industry are more expensive than ERF, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.56
EV/EBITDA 8.75
ERF.PA Per share dataERF.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ERF's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ERF has a very decent profitability rating, which may justify a higher PE ratio.
ERF's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.34
PEG (5Y)1.12
EPS Next 2Y14.58%
EPS Next 3Y14%

More info and screens

4

5. Dividend

5.1 Amount

ERF has a yearly dividend return of 0.91%, which is pretty low.
Compared to an average industry Dividend Yield of 0.71, ERF pays a better dividend. On top of this ERF pays more dividend than 85.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.39, ERF's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.91%

5.2 History

On average, the dividend of ERF grows each year by 16.51%, which is quite nice.
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
ERF.PA Yearly Dividends per shareERF.PA Yearly Dividends per shareYearly Dividends per share 2018 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

27.77% of the earnings are spent on dividend by ERF. This is a low number and sustainable payout ratio.
The dividend of ERF is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP27.77%
EPS Next 2Y14.58%
EPS Next 3Y14%
ERF.PA Yearly Income VS Free CF VS DividendERF.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
ERF.PA Dividend Payout.ERF.PA Dividend Payout, showing the Payout Ratio.ERF.PA Dividend Payout.PayoutRetained Earnings

More info and screens

EUROFINS SCIENTIFIC

EPA:ERF (8/14/2025, 7:00:00 PM)

67.52

+0.72 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-23 2025-07-23/dmh
Earnings (Next)10-21 2025-10-21
Inst Owners34.16%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap12.30B
Analysts70
Price Target64.9 (-3.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.91%
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP27.77%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.57%
PT rev (3m)9.3%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-0.29%
Valuation
Industry RankSector Rank
PE 20.46
Fwd PE 18.96
P/S 1.77
P/FCF 15.56
P/OCF 9.33
P/B 2.3
P/tB N/A
EV/EBITDA 8.75
EPS(TTM)3.3
EY4.89%
EPS(NY)3.56
Fwd EY5.27%
FCF(TTM)4.34
FCFY6.43%
OCF(TTM)7.24
OCFY10.72%
SpS38.16
BVpS29.31
TBVpS-1.59
PEG (NY)1.34
PEG (5Y)1.12
Profitability
Industry RankSector Rank
ROA 3.24%
ROE 6.61%
ROCE 11.86%
ROIC 9.18%
ROICexc 9.87%
ROICexgc 31.79%
OM 14.97%
PM (TTM) 5.08%
GM 22.33%
FCFM 11.37%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexcg growth 3Y-18.17%
ROICexcg growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score8
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 4.57
Debt/EBITDA 1.81
Cap/Depr 76.4%
Cap/Sales 7.6%
Interest Coverage 9.11
Cash Conversion 76.13%
Profit Quality 224%
Current Ratio 1.16
Quick Ratio 1.09
Altman-Z 2.86
F-Score8
WACC7.25%
ROIC/WACC1.27
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)14.98%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%13.46%
EPS Next Y15.29%
EPS Next 2Y14.58%
EPS Next 3Y14%
EPS Next 5Y13.47%
Revenue 1Y (TTM)6.7%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%6.87%
Revenue Next Year5.99%
Revenue Next 2Y6.12%
Revenue Next 3Y6.4%
Revenue Next 5Y6.47%
EBIT growth 1Y23.67%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year87.7%
EBIT Next 3Y30.85%
EBIT Next 5Y22.29%
FCF growth 1Y68.95%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y29.56%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%